{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:21:57Z","timestamp":1782966117101,"version":"3.54.5"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2012,2,14]],"date-time":"2012-02-14T00:00:00Z","timestamp":1329177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100003197","name":"Italian Medicines Agency","doi-asserted-by":"publisher","award":["FARM7SJX"],"award-info":[{"award-number":["FARM7SJX"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background.<\/jats:title><jats:p>Recurrence of hepatocellular carcinoma (HCC) is a major problem after surgical or ablative treatments. The aim of this prospective, single-center, placebo-controlled, randomized, double-blind clinical study was to evaluate the effectiveness of transarterial chemoembolization (TACE) combined with sorafenib as a sequential treatment regimen in delaying time to progression (TTP) of intermediate-stage HCC in patients with chronic hepatitis C virus (HCV) infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and Methods.<\/jats:title><jats:p>Between October, 2007 and January, 2011, 80 HCV-infected patients with Barcelona Clinic Liver Cancer stage B HCC underwent the TACE procedure. All had Child-Pugh class A disease. They were randomized 1:1 to receive sorafenib at a dose of 400 mg twice daily or placebo. Endpoints were the TTP and the rates of adverse events and toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Sixty-two of 80 patients (77%), 31 in the sorafenib group and 31 in the control group, completed the study. The median TTP was 9.2 months in the sorafenib group and 4.9 months in the placebo group (hazard ratio, 2.5; 95% confidence interval, 1.66\u20137.56; p &amp;lt; .001). Metachronous, multicentric HCC progression occurred less frequently in sorafenib-treated patients (p &amp;lt; .05). Adverse reactions to sorafenib caused withdrawal from the study of 9 (22%) patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>A conventional TACE procedure followed by sorafenib treatment resulted in a significantly longer TTP in patients with intermediate-stage HCV-related HCC, with no unexpected side effects.<\/jats:p><\/jats:sec>","DOI":"10.1634\/theoncologist.2011-0313","type":"journal-article","created":{"date-parts":[[2012,2,15]],"date-time":"2012-02-15T04:52:52Z","timestamp":1329281572000},"page":"359-366","source":"Crossref","is-referenced-by-count":125,"title":["Transarterial Chemoembolization Plus Sorafenib: A Sequential Therapeutic Scheme for HCV-Related Intermediate-Stage Hepatocellular Carcinoma: A Randomized Clinical Trial"],"prefix":"10.1093","volume":"17","author":[{"given":"Domenico","family":"Sansonno","sequence":"first","affiliation":[{"name":"a Liver Unit, Department of Internal Medicine and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Lauletta","sequence":"additional","affiliation":[{"name":"a Liver Unit, Department of Internal Medicine and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabino","family":"Russi","sequence":"additional","affiliation":[{"name":"a Liver Unit, Department of Internal Medicine and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"Conteduca","sequence":"additional","affiliation":[{"name":"a Liver Unit, Department of Internal Medicine and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Sansonno","sequence":"additional","affiliation":[{"name":"b Medical Genetics, Department of Biomedical Sciences, University of Foggia Medical School, Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Dammacco","sequence":"additional","affiliation":[{"name":"a Liver Unit, Department of Internal Medicine and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,2,14]]},"reference":[{"issue":"suppl 4","key":"2021122308254430600_B1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1634\/theoncologist.2010-S4-23","article-title":"The challenge of prognosis and staging for hepatocellular carcinoma","volume":"15","author":"Marrero","year":"2010","journal-title":"The Oncologist"},{"key":"2021122308254430600_B2","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra1001683","article-title":"Hepatocellular carcinoma","volume":"365","author":"El-Serag","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122308254430600_B3","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2006.08.002","article-title":"Large liver cell dysplasia: A controversial entity","volume":"45","author":"Park","year":"2006","journal-title":"J Hepatol"},{"key":"2021122308254430600_B4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/(SICI)1097-0142(19970701)80:1<22::AID-CNCR4>3.0.CO;2-H","article-title":"In situ simultaneous detection of hepatitis C virus RNA and hepatitis C virus-related antigens in hepatocellular carcinoma","volume":"80","author":"Sansonno","year":"1997","journal-title":"Cancer"},{"key":"2021122308254430600_B5","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2741\/3718","article-title":"Chemoprevention of hepatocellular carcinoma by acyclic retinoid","volume":"16","author":"Shimizu","year":"2011","journal-title":"Front Biosci"},{"key":"2021122308254430600_B6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/CJI.0b013e3182048c4e","article-title":"Possibility of adoptive immunotherapy with peripheral blood-derived CD3\u2212CD56+ and CD3+CD56+ cells for inducing antihepatocellular carcinoma and antihepatitis C virus activity","volume":"34","author":"Doskali","year":"2011","journal-title":"J Immunother"},{"key":"2021122308254430600_B7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/SLA.0b013e31820d944f","article-title":"Hepatocellular carcinoma: Current management and perspectives for the future","volume":"253","author":"Rahbari","year":"2011","journal-title":"Ann Surg"},{"key":"2021122308254430600_B8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hon.886","article-title":"Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: A pilot clinical trial","volume":"27","author":"Olioso","year":"2009","journal-title":"Hematol Oncol"},{"key":"2021122308254430600_B9","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1002\/1097-0142(20010615)91:12<2378::AID-CNCR1271>3.0.CO;2-2","article-title":"Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: Metaanalysis of three randomized controlled trials","volume":"91","author":"Ono","year":"2001","journal-title":"Cancer"},{"issue":"suppl 6","key":"2021122308254430600_B10","first-page":"S6-18","article-title":"Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: A prospective randomized study","volume":"24","author":"Ono","year":"1997","journal-title":"Semin Oncol"},{"key":"2021122308254430600_B11","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1593\/neo.91872","article-title":"Impact of metronomic UFT\/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma","volume":"12","author":"Tang","year":"2010","journal-title":"Neoplasia"},{"key":"2021122308254430600_B12","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/hep.21341","article-title":"Uracil-tegafur as an adjuvant for hepatocellular carcinoma: A randomized trial","volume":"44","author":"Hasegawa","year":"2006","journal-title":"Hepatology"},{"key":"2021122308254430600_B13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00280-006-0393-4","article-title":"Sorafenib (BAY 43\u20139006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models","volume":"59","author":"Chang","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122308254430600_B14","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122308254430600_B15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"2021122308254430600_B16","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1053\/j.gastro.2004.09.032","article-title":"Chemoembolization for hepatocellular carcinoma","volume":"125","author":"Bruix","year":"2004","journal-title":"Gastroenterology"},{"key":"2021122308254430600_B17","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1572-0241.2007.01712.x","article-title":"Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): The role of angiogenesis and invasiveness","volume":"103","author":"Sergio","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"2021122308254430600_B18","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1111\/j.1349-7006.2008.00909.x","article-title":"Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients","volume":"99","author":"Shim","year":"2008","journal-title":"Cancer Sci"},{"key":"2021122308254430600_B19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2036.2011.04697.x","article-title":"The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma","volume":"34","author":"Cabrera","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"2021122308254430600_B20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2362.2009.02226.x","article-title":"Feasibility and challenges of independent research on drugs: The Italian medicines agency (AIFA) experience","volume":"40","author":"Italian Medicines Agency (AIFA) Research & Development Working Group","year":"2010","journal-title":"Eur J Clin Invest"},{"key":"2021122308254430600_B21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"2021122308254430600_B22","volume-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Topic E 6: Guideline for Good Clinical Practice","author":"European Medicines Agency"},{"key":"2021122308254430600_B23","volume-title":"Recommendations Guiding Physicians in Biomedical Research Involving Human Subjects, Adopted by the 18th World Medical Assembly, Helsinki, Finland, June, Amended by 48th General Assembly, Somerset West, South Africa, 1996","author":"World Medical Association Declaration of Helsinki"},{"issue":"suppl 1","key":"2021122308254430600_B24","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1053\/j.gastro.2004.09.027","article-title":"Computed tomographic imaging of hepatocellular carcinoma","volume":"127","author":"Baron","year":"2004","journal-title":"Gastroenterology"},{"key":"2021122308254430600_B25","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2214\/ajr.175.3.1750699","article-title":"Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma","volume":"175","author":"Takayasu","year":"2000","journal-title":"AJR Am J Roentgenol"},{"key":"2021122308254430600_B26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.1840100119","article-title":"A 5-year experience of lipiodolization: Selective regional chemotherapy for 200 patients with hepatocellular carcinoma","volume":"10","author":"Kanematsu","year":"1989","journal-title":"Hepatology"},{"key":"2021122308254430600_B27","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1586\/14737140.8.11.1743","article-title":"Combined approach to hepatocellular carcinoma: A new treatment concept for nonresectable disease","volume":"8","author":"Strebel","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"2021122308254430600_B28","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"2021122308254430600_B29","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","article-title":"Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis","volume":"132","author":"El-Serag","year":"2007","journal-title":"Gastroenterology"},{"key":"2021122308254430600_B30","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/01.sla.0000225126.56483.b3","article-title":"Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma","volume":"244","author":"Sasaki","year":"2006","journal-title":"Ann Surg"},{"issue":"suppl 1","key":"2021122308254430600_B31","doi-asserted-by":"crossref","first-page":"S294","DOI":"10.1053\/j.gastro.2004.09.044","article-title":"Prevention of hepatitis C virus-related hepatocellular carcinoma","volume":"127","author":"Heathcote","year":"2004","journal-title":"Gastroenterology"},{"key":"2021122308254430600_B32","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/MOT.0b013e328339837b","article-title":"Molecular signature for HCC: Role in predicting outcomes after liver transplant and selection for potential adjuvant treatment","volume":"15","author":"Schmidt","year":"2010","journal-title":"Curr Opin Organ Transplant"},{"key":"2021122308254430600_B33","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/onc.2010.594","article-title":"Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer","volume":"30","author":"McGivern","year":"2011","journal-title":"Oncogene"},{"key":"2021122308254430600_B34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/1479-5876-8-109","article-title":"Targeting the inflammation in HCV-associated hepatocellular carcinoma: A role in the prevention and treatment","volume":"8","author":"Castello","year":"2010","journal-title":"J Transl Med"},{"key":"2021122308254430600_B35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1055\/s-0030-1247131","article-title":"Molecular classification and novel targets in hepatocellular carcinoma: Recent advancements","volume":"30","author":"Hoshida","year":"2010","journal-title":"Semin Liver Dis"},{"key":"2021122308254430600_B36","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1634\/theoncologist.2010-0180","article-title":"Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: Results of a phase I study","volume":"15","author":"Dufour","year":"2010","journal-title":"The Oncologist"},{"key":"2021122308254430600_B37","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1200\/JCO.2011.37.1021","article-title":"Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma","volume":"29","author":"Pawlik","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/pdf\/10.1634\/theoncologist.2011-0313","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/full-xml\/10.1634\/theoncologist.2011-0313","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/3\/359\/41872904\/oncolo_17_3_359.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/3\/359\/41872904\/oncolo_17_3_359.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T19:02:29Z","timestamp":1713553349000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/17\/3\/359\/6403249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,14]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2012,2,14]]},"published-print":{"date-parts":[[2012,3,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2011-0313","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,3,1]]},"published":{"date-parts":[[2012,2,14]]}}}